11 min read
Monthly FDA Guidance and Regulatory News Review - June 2026
This June 2026 regulatory update focuses on advancing innovative drug development through updated guidance on...
Meet Veristat in Boston at the Pharmacovigilance USA Conference
2-3 May 2024
We are delighted to announce that Veristat will be attending the 35th annual Pharmacovigilance (PV) USA conference. Don´t miss the opportunity to meet our team of highly experienced PV professionals, dedicated to ensuring the fulfillment of your regulatory requirements through sound processes and efficient systems to reduce your risk.
Veristat supports successful pre-approval and post-market PV and Medical Information (MI) expertise for pharmaceutical drugs, (both branded and generic), biologics, radiopharmaceutical drugs, natural health products, and medical devices.
Be certain, be inspection-ready, and keep your patients protected - with Veristat Pharmacovigilance experts on your side. Connect with us at the conference and learn more about how Veristat is making a difference.
Veristat team member, Alan Braverman, Senior Business Development Director, will be at the venue, ready to listen to your needs and share more about Veristat’s expertise. Arrange a meeting today! Complete the form on the right side of this page and we will confirm the date and time.
Website: 35th Pharmacovigilance USA 2024
Meet with us at the Pharmacovigilance USA Conference 2024 by filling out the form below.
11 min read
Jul 7, 2026 Veristat Blog
This June 2026 regulatory update focuses on advancing innovative drug development through updated guidance on...
2 min read
Jul 2, 2026 Veristat Blog
June 22, 2026
What the FDA's prior knowledge guidance means for natural history evidence and shared datasets
On June 2,...